Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
about
Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment.IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.Squamous cell carcinoma of the head and neck in the elderly.Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.Multi-isocentric 4π volumetric-modulated arc therapy approach for head and neck cancer.Implementing web-based ping-pong-type e-communication to enhance staff satisfaction, multidisciplinary cooperation, and clinical effectiveness: A SQUIRE-compliant quality-improving studyCellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment.Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc.Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice.
P2860
Q33412010-9F16D75D-27F1-445B-80EF-951D6305105FQ34568221-21136D48-688F-4CCA-B3B7-11AFB6439F27Q37116524-4483BA57-ACBA-48C7-AC75-D5091F03A978Q37392126-2F4D54A0-7227-4762-8DEC-C697AEC2CD33Q38015697-245A56AB-3078-42C8-A95D-3AE19AE82600Q38638148-B1D8831C-8FEC-453D-A9A9-69FC0F05527EQ39012095-84ABD6DA-F8B0-48B7-B8EA-DC6731E60AD4Q39300555-9D7B4282-E310-4F7C-BECE-D6872852ECCEQ41183357-D9B7FFE0-2423-45B4-8748-9FB42FD4E1B4Q43447566-802FF0AF-C9F4-47F0-99D5-066955EF362DQ44481582-7A77DF90-5DF7-4ED3-8839-EF610B113318Q52856838-A8F8CDCD-0E35-408F-BA3A-6A7D2DED8D26Q53313058-F959A50E-56BA-4108-B2D8-88E0BFA58E1B
P2860
Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prospective phase II trial of ...... motherapy-ineligible patients.
@ast
Prospective phase II trial of ...... motherapy-ineligible patients.
@en
type
label
Prospective phase II trial of ...... motherapy-ineligible patients.
@ast
Prospective phase II trial of ...... motherapy-ineligible patients.
@en
prefLabel
Prospective phase II trial of ...... motherapy-ineligible patients.
@ast
Prospective phase II trial of ...... motherapy-ineligible patients.
@en
P2093
P2860
P50
P921
P1476
Prospective phase II trial of ...... motherapy-ineligible patients.
@en
P2093
A Dragonetti
A Fogliata
G Reggiori
I Garassino
M Bignardi
P2860
P2888
P356
10.1007/S00066-011-0006-Y
P577
2011-12-24T00:00:00Z
P5875
P6179
1001727394